The drug consists of Nirmatrelvir tablets, which are co-packaged and co-administered with Ritonavir tablets.
Strides Pharma Science on Monday announced a sub-licensing agreement with the Medicines Patent Pool (MPP) to commercialise a generic version of Pfizer’s Covid-19 oral treatment in 95 low and middle-income markets. Pfizer’s Covid-19 oral treatment has received the US Food and Drug Administration’s (USFDA) emergency use authorisation for Covid-19 oral antiviral treatment.
Branded as Kovidax, the generic version of Pfizer’s oral drug will be launched in markets as part of Strides’ sub-licensing agreement with MPP. The product will be made at the company’s facility in Bengaluru. Strides said it had already secured its active pharmaceutical ingredients supplies through a preferred partnership arrangement.
The drug consists of Nirmatrelvir tablets, which are co-packaged and co-administered with Ritonavir tablets. The product has been authorised as a Covid-19 oral therapy for emergency use in the US and many other countries, amongst high-risk adults and high-risk paediatric patients.
Pfizer’s Covid-19 oral treatment has reduced the risk of hospitalisation or death by 89% within three days of symptom onset compared to a placebo.
It is administered as a dose of 300 mg of Nirmatrelvir with 100 mg tablet of Ritonavir, given twice daily for five days.
For all the latest Life Style News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
